Study to Estimate How Common it is to Have Genetic Variants Associated With NAFLD
NCT ID: NCT04494360
Last Updated: 2025-03-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
830 participants
OBSERVATIONAL
2020-08-07
2022-10-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genetic Studies of Non-Alcoholic Fatty Liver Disease
NCT01629095
Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)
NCT05423327
Association of Genes to Resistance to Weight Loss in Obese Patients
NCT00858221
A Study to Compare Genetic Variations of IGF-I and IGF-II
NCT01329523
Genetic Epidemiology of Primary Biliary Cirrhosis (PBC)
NCT01161953
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy Participants
Healthy participants (men and women) who have, or are likely to have, NAFLD will be enrolled in the study.
No intervention
No investigational medicinal product will be administered as a part of this study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
No investigational medicinal product will be administered as a part of this study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women must be of non-childbearing potential, defined as either: a.) Postmenopausal or b.) Permanently sterile
* Must be willing to provide a deoxyribonucleic acid (DNA) sample for assessment of genetic variants associated with NAFLD
* Must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study
Exclusion Criteria
* Excessive use of alcohol within 2 years prior to the study
* Body mass index greater than (\>) 40 kilogram per meter square (kg/m\^2)
* Evidence of other active (acute or chronic) liver disease other than NAFLD/ Nonalcoholic steatohepatitis (NASH)
* History of bariatric surgery or planning to undergo bariatric surgery within the next year
* Inability to undergo magnetic resonance imaging (MRI)
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Janssen Research & Development, LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Janssen Research & Development, LLC Clinical Trial
Role: STUDY_DIRECTOR
Janssen Research & Development, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Centers of America, LLC
Hollywood, Florida, United States
PRA Health Sciences
Lenexa, Kansas, United States
Endeavor Clinical Trials, LLC
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NOPRODNAS0001
Identifier Type: OTHER
Identifier Source: secondary_id
CR108830
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.